Tempest Therapeutics Announces Resignation of Three Board Directors
On May 22, 2026, Tempest Therapeutics, Inc. announced the concurrent resignations of three members of its Board of Directors: Mr. Stephen Brady, Mr. Michael Raab, and Ms. Christine Pellizzari. According to the filing, these resignations were not the result of any disagreements with the Company regarding its operations, policies, or practices. In connection with their departures, the Company entered into Separation Agreements with each individual. Under the terms of these agreements, the directors agreed to waive all accrued and unpaid retainer fees owed under the Companyβs non-employee director compensation program. The separation does not impact their existing stock option awards or ownership of capital stock. Furthermore, their indemnification agreements will remain in effect, with underlying rights preserved for six years following their separation. Matthew Angel, the President and CEO, signed the report on behalf of the Company. Full details of the Separation Agreements are expected to be filed with the Company's next Quarterly Report.